A glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide 10 mg is a medication prescribed for the management of type 2 diabetes mellitus. It is offered in two forms: an injectable solution for subcutaneous use and an oral tablet formulation.
The medication functions by emulating the effects of the body’s endogenous GLP-1 hormone. Specifically, it enhances the secretion of insulin—a hormone that regulates blood sugar—while simultaneously inhibiting the release of glucagon, another hormone that raises blood sugar levels. As a result, Semaglutide effectively reduces blood glucose concentrations. In addition to its blood sugar-lowering properties, Semaglutide exhibits several other beneficial effects:
Enhanced Insulin Production:
Semaglutide stimulates the pancreas to secrete more insulin when blood sugar levels are elevated.
Delayed Gastric Emptying:
The medication decelerates the rate at which the stomach empties, contributing to a sensation of satiety and decreased caloric intake.
Improved Glycemic Control:
Semaglutide successfully diminishes blood glucose levels and lowers glycated hemoglobin (HbA1c) values.
Clinical studies have demonstrated that Semaglutide can facilitate weight loss in individuals diagnosed with type 2 diabetes.
Research indicates that Semaglutide may be associated with a decreased likelihood of experiencing cardiovascular events.
Semaglutide interacts with appetite-regulating centers in the brain, curbing the urge to eat and promoting satisfaction with smaller meal portions.
Recommended Dosage and Administration:
The initial recommended dosage of subcutaneous Semaglutide is 0.25 mg, administered once per week. This starting dose is designed to mitigate gastrointestinal adverse effects and is not intended for glycemic control. After a four-week period, the dosage should be escalated to 0.5 mg once weekly. Subsequent dose adjustments to 1.0 mg once weekly may be considered based on individual response and tolerability, following at least four weeks on the 0.5 mg dose.
Semaglutide injections can be administered at any time of the day, irrespective of meal timing. The injection sites include the abdomen, thigh, or upper arm, and it is advisable to alternate injection sites to minimize the risk of lipodystrophy.
Unused Semaglutide pens should be refrigerated. Once a pen is in use, it may be stored at room temperature for a maximum duration of 56 days.